Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Lei Bi, Fuqiong Zhou, Peng Meng, Bo Tang, Yidan Ren, Yunshan Wang, Yu-Cui Jiang, Weiping Chen, Qin Wang, Chuanxin Wang, Maoxiao Feng, Yuli Wang, Feiyan Chen, Qinlian Jiao, Lutao Du
Publikováno v:
Cancer Research. 81:2015-2028
Hepatocellular carcinoma (HCC) contains a subset of cancer stem cells (CSC) that cause tumor recurrence, metastasis, and chemical resistance. Histone deacetylase 11 (HDAC11) mediates diverse immune functions and metabolism, yet little is known about
Autor:
Nikhil C. Munshi, Daisuke Tsuchimoto, Mei Yin, Allison J. Janocha, Yi Hu, Hua Fang, Shan Yan, Thomas LaFramboise, Li Xue, Alex Mejia-Garcia, Chen Li, Chun Yang, Jennifer S. Yu, Jianhong Lin, Kenneth C. Anderson, Chuanfeng Fang, Yusaku Nakabeppu, Qing Y. Zheng, Tania Amorim, Xin Qi, Leal Herlitz, Faiz Anwer, Jenny Lin, Jack Khouri, Mohsin Maqbool, Ariel Kwart, Xiaofeng Jiang, Jianjun Zhao
Publikováno v:
Cancer Res
Cisplatin chemotherapy is standard care for many cancers but is toxic to the kidneys. How this toxicity occurs is uncertain. In this study, we identified apurinic/apyrimidinic endonuclease 2 (APE2) as a critical molecule upregulated in the proximal t
Autor:
Jeremy Bobera, Charlotte R. Feddersen, Sarah A. Mullen, Jesse D. Riordan, Lexy S. Wadsworth, Jacob L. Schillo, Adam J. Dupuy, Hayley R. Vaughn, Christopher S. Stipp, Brooke M. Jennings, Andrew P. Voigt, Afshin Varzavand, Eliot Y. Zhu
Publikováno v:
Cancer Research. 79:5074-5087
The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a BRAFV600E mutation. Unfortunately, the majority of patients eventually develop drug-resistant disease. We employed
Autor:
Luisa Izzi, H. Wang, Victor Cohen, Christian Couture, Nicole Bouchard, Jason Agulnik, Valerie Higenell, Normand Blais, Lise Tremblay, Cyrla Hoffert, Caroline Rousseau, Mathilde Couetoux du Tertre, Gerald Batist, Razvan Diaconescu, Maud Marques, Suzan McNamara, Vincent Pelsser, Karen Gambaro, Alan Spatz, Archana Srivastava
Publikováno v:
Molecular Cancer Therapeutics. 18:1628-1636
Rearrangements in the anaplastic lymphoma kinase (ALK) gene are found in approximately 5% of non–small cell lung carcinoma (NSCLC). Here, we present a comprehensive genomic landscape of 11 patients with ALK+ NSCLC and investigate its relationship w
Autor:
Michael B. Sporn, Di Zhang, Samir J. Ibrahim, Karen T. Liby, Ana S. Leal, Pamela A. Marshall, Carl E. Wagner, Pritika H. Shahani, San Raban, Peter W. Jurutka, Sarah Carapellucci, Jaskaran S. Bhogal
Publikováno v:
Cancer Prevention Research. 12:211-224
Rexinoids, selective ligands for retinoid X receptors (RXR), have shown promise in preventing many types of cancer. However, the limited efficacy and undesirable lipidemic side-effects of the only clinically approved rexinoid, bexarotene, drive the s
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Gregory J. Riely, Marc Ladanyi, Ryan Kim, Ken Suzawa, Matthew D. Hellmann, Helena A. Yu, Maria E. Arcila, Ahmet Zehir, Ai Ni, Bob T. Li, Michael F. Berger, Romel Somwar, Emmet Jordan, Mark G. Kris, David B. Solit
Publikováno v:
Clinical Cancer Research. 24:3108-3118
Purpose: To identify molecular factors that determine duration of response to EGFR tyrosine kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly profiled EGFR-mutant tumors prior to treatment and after progression on
Autor:
Byung-Gyu Kim, Hye Jin Ham, Jung-Guk Kim, Ji-Hyun Kim, Soo-Young Park, Keun-Gyu Park, Jung Yi Lee, Yeon-Kyung Choi, Se Young Jang, Mi Jin Kim, Hui-Jeon Jeon, Inkyu Lee
Publikováno v:
Molecular Cancer Research. 15:1230-1242
The tyrosine kinase inhibitor sorafenib is the only therapeutic agent approved for the treatment of advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib is high. Here, we report metabolic reprogramming in sorafenib-resistant
Autor:
Atsuko Ogino, T. Kosaka, Marzia Capelletti, Jihyun Choi, Hideki Endoh, Junko Tanizaki, Michael J. Eck, Dalia Ercan, Magda Bahcall, Raymond M. Paranal, Geoffrey R. Oxnard, Pasi A. Jänne, Amanda J. Redig, Antonio Calles, Claire E. Repellin, Christine A. Lydon
Publikováno v:
Cancer Research. 77:2712-2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non–small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazo
Autor:
Takatsugu Okegawa, Shuta Tomida, Suguru Hamada, Kikuo Nutahara, Hidetoshi Hayashi, Kazuko Sakai, Masato Terashima, Kazuto Nishio, Yu Nakamura, Yosuke Togashi, Yoshihiko Fujita, Eri Banno, Marco A. De Velasco, Hirokazu Nakahara
Publikováno v:
Molecular Cancer Therapeutics. 15:1988-1997
The prognosis for patients with advanced esophageal or head-and-neck squamous cell carcinoma (ESCC or HNSCC) remains poor, and the identification of additional oncogenes and their inhibitors is needed. In this study, we evaluated the sensitivities of